A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Official title

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Study identification

NCT ID

NCT07284849

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

Incyte Corporation

Industry

Enrollment

700 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Mar 5, 2026 (Actual)

Primary completion

Dec 29, 2028 (Estimated)

Completion

Sep 28, 2029 (Estimated)

Last update posted

Oct 9, 2026

2026 – 2029

United States locations

U.S. sites

75

U.S. states

30

U.S. cities

64

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 218 non-U.S. sites.